Listed

X4 Pharmaceuticals, Inc

XFORNasdaqCIK 1501697HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$8.8m, Q2 FY2026
Operating income−$16.4m, Q2 FY2026
Net income−$16.2m, Q2 FY2026
X4 Pharmaceuticals, Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure0.6Revenue, Q2 FY2024, three months to 2024-06-30$563.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure0.6Revenue, Q3 FY2024, three months to 2024-09-30$560.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure1.4Revenue, Q4 FY2024, three months to 2024-12-31$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure28.8Revenue, Q1 FY2025, three months to 2025-03-31$28.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure2.0Revenue, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure1.8Revenue, Q3 FY2025, three months to 2025-09-30$1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure2.6Revenue, Q4 FY2025, three months to 2025-12-31$2.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure2.7Revenue, Q1 FY2026, three months to 2026-03-31$2.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure8.8Revenue, Q2 FY2026, three months to 2026-06-30$8.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Cost of revenue$m0.0Cost of revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure0.0Cost of revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.0Cost of revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure0.3Cost of revenue, Q2 FY2024, three months to 2024-06-30$268.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure0.2Cost of revenue, Q3 FY2024, three months to 2024-09-30$227.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure0.3Cost of revenue, Q4 FY2024, three months to 2024-12-31$302.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure4.7Cost of revenue, Q1 FY2025, three months to 2025-03-31$4.7m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure0.3Cost of revenue, Q2 FY2025, three months to 2025-06-30$326.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure0.4Cost of revenue, Q3 FY2025, three months to 2025-09-30$351.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure0.4Cost of revenue, Q4 FY2025, three months to 2025-12-31$364.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.6Cost of revenue, Q1 FY2026, three months to 2026-03-31$598.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure1.6Cost of revenue, Q2 FY2026, three months to 2026-06-30$1.6m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Research and development$m19.1Research and development, Q3 FY2023, three months to 2023-09-30$19.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure15.3Research and development, Q4 FY2023, three months to 2023-12-31$15.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure19.9Research and development, Q1 FY2024, three months to 2024-03-31$19.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure20.9Research and development, Q2 FY2024, three months to 2024-06-30$20.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure19.2Research and development, Q3 FY2024, three months to 2024-09-30$19.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure21.7Research and development, Q4 FY2024, three months to 2024-12-31$21.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure18.5Research and development, Q1 FY2025, three months to 2025-03-31$18.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure18.4Research and development, Q2 FY2025, three months to 2025-06-30$18.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure17.3Research and development, Q3 FY2025, three months to 2025-09-30$17.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure18.5Research and development, Q4 FY2025, three months to 2025-12-31$18.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure15.5Research and development, Q1 FY2026, three months to 2026-03-31$15.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure15.1Research and development, Q2 FY2026, three months to 2026-06-30$15.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Operating income$m(27.2)Operating income, Q3 FY2023, three months to 2023-09-30−$27.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure(25.2)Operating income, Q4 FY2023, three months to 2023-12-31−$25.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(37.3)Operating income, Q1 FY2024, three months to 2024-03-31−$37.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure71.1Operating income, Q2 FY2024, three months to 2024-06-30$71.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure(34.5)Operating income, Q3 FY2024, three months to 2024-09-30−$34.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure(35.7)Operating income, Q4 FY2024, three months to 2024-12-31−$35.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(9.4)Operating income, Q1 FY2025, three months to 2025-03-31−$9.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(26.2)Operating income, Q2 FY2025, three months to 2025-06-30−$26.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(27.5)Operating income, Q3 FY2025, three months to 2025-09-30−$27.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure(23.7)Operating income, Q4 FY2025, three months to 2025-12-31−$23.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(20.3)Operating income, Q1 FY2026, three months to 2026-03-31−$20.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(16.4)Operating income, Q2 FY2026, three months to 2026-06-30−$16.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Interest expense$m1.6Interest expense, Q3 FY2023, three months to 2023-09-30$1.6m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure1.9Interest expense, Q4 FY2023, three months to 2023-12-31$1.9m. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-21, accession 0001628280-24-012578. Derived: 12-month figure less the 9-month figure.Report this figure1.9Interest expense, Q1 FY2024, three months to 2024-03-31$1.9m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure2.2Interest expense, Q2 FY2024, three months to 2024-06-30$2.2m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure2.4Interest expense, Q3 FY2024, three months to 2024-09-30$2.4m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure2.3Interest expense, Q4 FY2024, three months to 2024-12-31$2.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure2.2Interest expense, Q1 FY2025, three months to 2025-03-31$2.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure2.2Interest expense, Q2 FY2025, three months to 2025-06-30$2.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure2.3Interest expense, Q3 FY2025, three months to 2025-09-30$2.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure2.2Interest expense, Q4 FY2025, three months to 2025-12-31$2.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure2.1Interest expense, Q1 FY2026, three months to 2026-03-31$2.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure2.2Interest expense, Q2 FY2026, three months to 2026-06-30$2.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$26.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$33.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$19.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$18.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$15.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure0.3Income tax, Q4 FY2024, three months to 2024-12-31$258.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$34.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$37.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(0.0)Income tax, Q3 FY2025, three months to 2025-09-30−$30.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$2.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Net income$m(2.3)Net income, Q3 FY2023, three months to 2023-09-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure(19.1)Net income, Q4 FY2023, three months to 2023-12-31−$19.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(51.8)Net income, Q1 FY2024, three months to 2024-03-31−$51.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure90.8Net income, Q2 FY2024, three months to 2024-06-30$90.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure(36.7)Net income, Q3 FY2024, three months to 2024-09-30−$36.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure(39.8)Net income, Q4 FY2024, three months to 2024-12-31−$39.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.3Net income, Q1 FY2025, three months to 2025-03-31$282.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(25.7)Net income, Q2 FY2025, three months to 2025-06-30−$25.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(29.8)Net income, Q3 FY2025, three months to 2025-09-30−$29.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure(23.9)Net income, Q4 FY2025, three months to 2025-12-31−$23.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(20.2)Net income, Q1 FY2026, three months to 2026-03-31−$20.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(16.2)Net income, Q2 FY2026, three months to 2026-06-30−$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Diluted EPS$ per share(0.01)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figurenot reported(7.77)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$7.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure13.57Diluted EPS, Q2 FY2024, three months to 2024-06-30$13.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure(5.48)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$5.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figurenot reported0.04Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(3.47)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(0.69)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figurenot reported(0.16)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(0.13)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Basic EPS$ per share(0.01)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figurenot reported(7.77)Basic EPS, Q1 FY2024, three months to 2024-03-31−$7.77 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure13.59Basic EPS, Q2 FY2024, three months to 2024-06-30$13.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure(5.48)Basic EPS, Q3 FY2024, three months to 2024-09-30−$5.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figurenot reported0.04Basic EPS, Q1 FY2025, three months to 2025-03-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(3.47)Basic EPS, Q2 FY2025, three months to 2025-06-30−$3.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure(0.69)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figurenot reported(0.16)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(0.13)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure

Balance sheet

Cash and equivalents$195.1m, Q2 FY2026
Long-term debt$75.0m, Q2 FY2026
Shareholders' equity$155.5m, Q2 FY2026
X4 Pharmaceuticals, Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m132Cash and equivalents, Q3 FY2023, at 2023-09-30$131.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure99.2Cash and equivalents, FY2023, at 2023-12-31$99.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-26, accession 0001628280-25-014805.Report this figure60.5Cash and equivalents, Q1 FY2024, at 2024-03-31$60.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure147Cash and equivalents, Q2 FY2024, at 2024-06-30$147.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure97.4Cash and equivalents, Q3 FY2024, at 2024-09-30$97.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure55.7Cash and equivalents, FY2024, at 2024-12-31$55.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure40.3Cash and equivalents, Q1 FY2025, at 2025-03-31$40.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure39.2Cash and equivalents, Q2 FY2025, at 2025-06-30$39.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure69.6Cash and equivalents, Q3 FY2025, at 2025-09-30$69.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure217Cash and equivalents, FY2025, at 2025-12-31$217.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure217Cash and equivalents, Q1 FY2026, at 2026-03-31$216.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure195Cash and equivalents, Q2 FY2026, at 2026-06-30$195.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Current assets$m148Current assets, Q3 FY2023, at 2023-09-30$147.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure122Current assets, FY2023, at 2023-12-31$122.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-26, accession 0001628280-25-014805.Report this figure87.3Current assets, Q1 FY2024, at 2024-03-31$87.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure175Current assets, Q2 FY2024, at 2024-06-30$175.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure143Current assets, Q3 FY2024, at 2024-09-30$143.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure112Current assets, FY2024, at 2024-12-31$112.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure95.7Current assets, Q1 FY2025, at 2025-03-31$95.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure72.9Current assets, Q2 FY2025, at 2025-06-30$72.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure133Current assets, Q3 FY2025, at 2025-09-30$132.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure262Current assets, FY2025, at 2025-12-31$261.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure242Current assets, Q1 FY2026, at 2026-03-31$242.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure219Current assets, Q2 FY2026, at 2026-06-30$218.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Total assets$m173Total assets, Q3 FY2023, at 2023-09-30$173.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure147Total assets, FY2023, at 2023-12-31$147.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-26, accession 0001628280-25-014805.Report this figure112Total assets, Q1 FY2024, at 2024-03-31$112.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure211Total assets, Q2 FY2024, at 2024-06-30$210.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure178Total assets, Q3 FY2024, at 2024-09-30$178.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure146Total assets, FY2024, at 2024-12-31$146.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure130Total assets, Q1 FY2025, at 2025-03-31$130.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure105Total assets, Q2 FY2025, at 2025-06-30$105.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure164Total assets, Q3 FY2025, at 2025-09-30$163.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure290Total assets, FY2025, at 2025-12-31$290.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure270Total assets, Q1 FY2026, at 2026-03-31$270.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure253Total assets, Q2 FY2026, at 2026-06-30$253.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Current liabilities$m25.4Current liabilities, Q3 FY2023, at 2023-09-30$25.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure22.9Current liabilities, FY2023, at 2023-12-31$22.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-26, accession 0001628280-25-014805.Report this figure23.5Current liabilities, Q1 FY2024, at 2024-03-31$23.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure28.9Current liabilities, Q2 FY2024, at 2024-06-30$28.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure29.3Current liabilities, Q3 FY2024, at 2024-09-30$29.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure32.9Current liabilities, FY2024, at 2024-12-31$32.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure25.9Current liabilities, Q1 FY2025, at 2025-03-31$25.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure22.9Current liabilities, Q2 FY2025, at 2025-06-30$22.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure23.5Current liabilities, Q3 FY2025, at 2025-09-30$23.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure25.8Current liabilities, FY2025, at 2025-12-31$25.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure23.8Current liabilities, Q1 FY2026, at 2026-03-31$23.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure19.4Current liabilities, Q2 FY2026, at 2026-06-30$19.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Total liabilities$m106Total liabilities, Q3 FY2023, at 2023-09-30$105.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure96.2Total liabilities, FY2023, at 2023-12-31$96.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-26, accession 0001628280-25-014805.Report this figure111Total liabilities, Q1 FY2024, at 2024-03-31$111.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure116Total liabilities, Q2 FY2024, at 2024-06-30$116.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure119Total liabilities, Q3 FY2024, at 2024-09-30$118.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure124Total liabilities, FY2024, at 2024-12-31$124.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure107Total liabilities, Q1 FY2025, at 2025-03-31$107.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure101Total liabilities, Q2 FY2025, at 2025-06-30$101.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure102Total liabilities, Q3 FY2025, at 2025-09-30$101.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure104Total liabilities, FY2025, at 2025-12-31$104.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure102Total liabilities, Q1 FY2026, at 2026-03-31$101.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure97.6Total liabilities, Q2 FY2026, at 2026-06-30$97.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Long-term debt$m55.0Long-term debt, Q3 FY2023, at 2023-09-30$55.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure54.6Long-term debt, FY2023, at 2023-12-31$54.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2024-03-21, accession 0001628280-24-012578.Report this figure55.0Long-term debt, Q1 FY2024, at 2024-03-31$55.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure75.0Long-term debt, Q2 FY2024, at 2024-06-30$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure75.0Long-term debt, Q3 FY2024, at 2024-09-30$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure75.0Long-term debt, FY2024, at 2024-12-31$75.0m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure75.0Long-term debt, Q1 FY2025, at 2025-03-31$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure75.0Long-term debt, Q2 FY2025, at 2025-06-30$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure75.0Long-term debt, Q3 FY2025, at 2025-09-30$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure75.0Long-term debt, FY2025, at 2025-12-31$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure75.0Long-term debt, Q1 FY2026, at 2026-03-31$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure75.0Long-term debt, Q2 FY2026, at 2026-06-30$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure
Current portion of debt$m0.0Current portion of debt, Q3 FY2023, at 2023-09-30$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure0.0Current portion of debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2024-03-21, accession 0001628280-24-012578.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m67.6Shareholders' equity, Q3 FY2023, at 2023-09-30$67.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure51.1Shareholders' equity, FY2023, at 2023-12-31$51.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-17, accession 0001501697-26-000018.Report this figure1.0Shareholders' equity, Q1 FY2024, at 2024-03-31$1.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure94.5Shareholders' equity, Q2 FY2024, at 2024-06-30$94.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure59.6Shareholders' equity, Q3 FY2024, at 2024-09-30$59.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure22.1Shareholders' equity, FY2024, at 2024-12-31$22.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure22.9Shareholders' equity, Q1 FY2025, at 2025-03-31$22.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure4.0Shareholders' equity, Q2 FY2025, at 2025-06-30$4.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure61.6Shareholders' equity, Q3 FY2025, at 2025-09-30$61.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure186Shareholders' equity, FY2025, at 2025-12-31$186.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure168Shareholders' equity, Q1 FY2026, at 2026-03-31$168.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure155Shareholders' equity, Q2 FY2026, at 2026-06-30$155.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure

Cash flow

Operating cash flow−$20.8m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
X4 Pharmaceuticals, Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(68.8)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$68.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure(27.7)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$27.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(33.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$33.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure(63.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$63.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure(34.0)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$34.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001501697-25-000043. Derived: 9-month figure less the 6-month figure.Report this figure(33.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$33.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(12.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$12.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(29.9)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$29.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001501697-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure(27.8)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$27.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001501697-25-000043. Derived: 9-month figure less the 6-month figure.Report this figure(15.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$15.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(19.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$19.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure(20.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$20.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001501697-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$8.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2024-11-13, accession 0001628280-24-047445. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$35.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-26, accession 0001628280-25-014805. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$59.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure0.1Capital expenditure, Q2 FY2024, three months to 2024-06-30$134.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-08-08, accession 0001628280-25-039327. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$92.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-05, accession 0001501697-25-000043. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$41.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-26, accession 0001628280-25-014805. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-08-08, accession 0001628280-25-039327. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-05, accession 0001501697-25-000043. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-03-17, accession 0001501697-26-000018. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Share repurchases$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)126.34m, Q2 FY2026
X4 Pharmaceuticals, Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q3 FY20232023-03-31Q3 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares83.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3083,211,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001628280-23-038334.Report this figure146Diluted shares (weighted), Q3 FY2023, three months to 2023-03-31145,967,476 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001628280-24-021120.Report this figure169Diluted shares (weighted), Q3 FY2023, three months to 2023-06-30168,737,764 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001628280-24-036127.Report this figure197Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30196,987,827 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001628280-24-047445.Report this figure6.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-316,666,386 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-01, accession 0001628280-25-021358.Report this figure6.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-306,693,376 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-08, accession 0001628280-25-039327.Report this figure6.7Diluted shares (weighted), Q3 FY2024, three months to 2024-09-306,695,509 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure6.9Diluted shares (weighted), Q1 FY2025, three months to 2025-03-316,869,084 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure7.4Diluted shares (weighted), Q2 FY2025, three months to 2025-06-307,412,990 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure43.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3043,272,773 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001501697-25-000043.Report this figure126Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31126,288,723 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001501697-26-000040.Report this figure126Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30126,344,020 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure

Shares outstanding: 99.15mShares outstanding, period not labelled, at 2026-07-3199,146,743 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001501697-26-000068.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. Listed shows no prices and gives no investment advice.